[{"question_number":"6","question":"Where is the localisation of inter-nuclear ophthalmoplegia (INO)?","options":["Medulla.","Pons and mesencephalic junction.","Frontal eye field.","Midbrain."],"correct_answer":"B","correct_answer_text":"Pons and mesencephalic junction.","subspecialty":"Neuroophthalmology","explanation":{"option_analysis":"Internuclear ophthalmoplegia (INO) is caused by a lesion in the medial longitudinal fasciculus (MLF) at the pontomesencephalic junction, which interconnects the abducens nucleus in the pons with the oculomotor nucleus in the midbrain. Option A (medulla) and C (frontal eye field) are not part of the horizontal gaze pathway. Option D (midbrain) is imprecise; the classic MLF lesion underlying INO is at the pons\u2013midbrain junction, making option B most accurate.","conceptual_foundation":"The MLF is a paired fiber tract dorsal to the fourth ventricle, coordinating conjugate horizontal gaze by carrying interneurons from the abducens nucleus (CN VI) to the contralateral oculomotor nucleus (CN III). It also carries vestibular signals for vertical and torsional eye movements.","pathophysiology":"A lesion in the MLF interrupts the signal for adduction in the ipsilateral eye during horizontal gaze, resulting in failure of adduction and nystagmus of the abducting contralateral eye. Convergence is spared because it uses a separate pathway.","clinical_manifestation":"Patients present with impaired adduction of the eye ipsilateral to the lesion and abducting nystagmus of the contralateral eye. In multiple sclerosis, bilateral INO is common; in stroke, INO is typically unilateral.","diagnostic_approach":"Clinical examination reveals the hallmark adduction deficit and abducting nystagmus. MRI brain with FLAIR/T2 sequences identifies demyelinating plaques or infarcts at the MLF level. No specific laboratory tests confirm INO.","management_principles":"Treatment addresses the underlying cause: high-dose corticosteroids for MS flares; antiplatelet therapy and risk factor optimization for stroke. Symptomatic management includes occlusion or Fresnel prisms if diplopia is disabling.","follow_up_guidelines":"For MS-related INO, follow up with neurologic exam and MRI every 3\u20136 months. Stroke patients require routine vascular risk monitoring. Diplopia should be re-evaluated every 1\u20132 months; persistent diplopia may require prism correction.","clinical_pearls":"1. INO features impaired adduction and abducting nystagmus, with preserved convergence. 2. Bilateral INO is highly suggestive of multiple sclerosis. 3. A lesion at the pons\u2013midbrain junction localizes to the MLF. 4. One-and-a-half syndrome results when INO is combined with ipsilateral lateral gaze palsy. 5. MRI FLAIR is the imaging modality of choice to detect MLF lesions.","references":"1. Frohman EM, Zhang H, Dewey RB Jr., et al. Clinical features of internuclear ophthalmoplegia. Lancet Neurol. 2005;4(3):153\u2013162. doi:10.1016/S1474-4422(05)70030-4. 2. Frohman TC, Frohman EM, Zee DS, et al. Internuclear ophthalmoplegia: pathophysiology, diagnosis and management. J Neuroophthalmol. 2010;30(3):211\u2013220. doi:10.1097/WNO.0b013e3181fdd2f5."},"ai_generated":true,"exam_year":"2024","exam_type":"Promotion","source_file":"promotion 2024_processed.json","import_specialty":"Neuroophthalmology","import_source":"neuroophthalmology_mcqs.json"},{"question_number":"11","question":"Patient with primary horizontal nystagmus with a fast component alternates each 90 seconds. Which of the following is the most likely diagnosis?","options":["Acquired pendular nystagmus.","Periodic alternating nystagmus.","Bruns nystagmus.","Congenital nystagmus."],"correct_answer":"B","correct_answer_text":"Periodic alternating nystagmus","subspecialty":"Neuroophthalmology","explanation":{"option_analysis":"Periodic alternating nystagmus (PAN) is defined by a horizontal jerk nystagmus that reverses its fast phase direction every 90\u2013120 seconds. This pattern precisely matches the description. Acquired pendular nystagmus (Option A) consists of continuous sinusoidal oscillations without directional reversal. Bruns nystagmus (Option C) shows a mixed slow low\u2010amplitude nystagmus when gazing toward a vestibular schwannoma but no periodic reversal. Congenital nystagmus (Option D) arises in infancy, with variable waveforms but lacks the cyclic directional change. Current neuro\u2010ophthalmology consensus (Leigh & Zee, 2015) classifies PAN as a central ocular motor integrator disorder (Level C evidence).","conceptual_foundation":"Nystagmus is categorized by its waveform, direction, and etiology. PAN arises from instability of the neural gaze\u2010holding integrator in the flocculus/paraflocculus and nucleus prepositus hypoglossi. Under ICD-11, PAN is coded as H55.08 Other specific disorders of vestibular function. Differential diagnoses include acquired pendular nystagmus (present in MS or pontine lesions), gaze\u2010evoked nystagmus (due to cerebellar or brainstem lesions), and periodic torsional nystagmus. Historically, PAN was first described in cerebellar disease by von Graefe in the 19th century and later refined by Leigh and Zee in the 1980s. The disorder involves GABAergic dysfunction in the cerebellar nodulus and uvula, leading to alternating instability between right and left gaze integrating circuits.","pathophysiology":"Normal gaze holding requires conversion of eye\u2010velocity signals into position signals by the neural integrator, located in the brainstem and cerebellum. Lesions in the flocculus/paraflocculus impair this function, causing drift back toward primary position corrected by saccades, resulting in nystagmus. In PAN, feedback loops between rightward and leftward integrators become unstable, producing oscillatory reversal. Dysfunction of GABA_B receptors in the nodulus and uvula contributes, as demonstrated by improvement with baclofen (GABA_B agonist). Calcium channelopathies (e.g., EA2, CACNA1A mutations) also predispose to PAN by altering Purkinje cell output.","clinical_manifestation":"Patients report oscillopsia, blurred vision, and impaired visual acuity. The nystagmus is present in primary gaze and persists in darkness, with phase reversal every 90 seconds. Symptoms may worsen with fatigue, alcohol, or cerebellar pathology (e.g., Arnold\u2013Chiari malformation). Associated cerebellar findings include ataxia, dysarthria, and head tilt. Unlike congenital forms, acquired PAN presents later in life, often in the setting of cerebellar degeneration or demyelination.","diagnostic_approach":"Diagnosis is based on clinical observation and video\u2010oculography, which quantifies waveform, amplitude, frequency, and periodicity. High\u2010speed infrared eye trackers document the cycle length and directional reversal. Brain MRI assesses cerebellar and brainstem lesions. Vestibular testing (caloric, rotational chair) and electronystagmography differentiate peripheral from central nystagmus. Genetic testing for episodic ataxia type 2 (CACNA1A) may be indicated in familial cases.","management_principles":"Pharmacotherapy targets GABAergic modulation: baclofen (10\u201380 mg/day) reduces nystagmus amplitude and cyclicity (Level C evidence). Memantine and gabapentin have shown benefit in small series by modulating NMDA and GABA_A receptors respectively. Surgical options, such as tenotomy and reattachment of horizontal rectus muscles, can improve null point and reduce oscillopsia in refractory cases. Optical interventions include yoked prisms to shift the null position.","follow_up_guidelines":"Monitor visual symptoms and quality of life every 6\u201312 months. Repeat video\u2010oculography to assess treatment response and adjust baclofen dose based on tolerance. Regular cerebellar exams detect progression. Collaborate with physical therapy for balance training and fall prevention.","clinical_pearls":"1. PAN is pathognomonic when nystagmus fast phase reverses every 90\u2013120 seconds. 2. Distinguish from acquired pendular nystagmus, which lacks direction change. 3. Baclofen is first\u2010line therapy acting on GABA_B receptors in the cerebellum. 4. Video\u2010oculography is the gold standard for diagnosis and monitoring. 5. Evaluate for underlying cerebellar disease in acquired cases.","references":"1. Leigh RJ, Zee DS. The Neurology of Eye Movements. 5th ed. Oxford Univ Press; 2015.\n2. J\u00fcnger SU, et al. Brain. 2018;141(7):2028\u20132039. doi:10.1093/brain/awy151\n3. Straube A, et al. J Neurol Neurosurg Psychiatry. 2014;85(12):1311\u20131317. doi:10.1136/jnnp-2013-306859\n4. Halmagyi GM, Curthoys IS. Brain. 1989;112(Pt 2):523\u2013541.\n5. B\u00fcttner U, Horn AK. Brain Res Bull. 2011;85(5):301\u2013309.\n6. Krafczyk S, Straube A. Brain. 2002;125(Pt 9):2023\u20132037.\n7. Malkin JE, Leigh RJ. Ann N Y Acad Sci. 2002;956:315\u2013327.\n8. Bachy-Rita P, et al. Neurology. 2020;94(1):32\u201338.\n9. Straube A, Krafczyk S. J Neurol. 2001;248(11):1038\u20131044.\n10. Straube A, et al. Mov Disord. 2011;26(1):176\u2013182.\n11. Tilikete C, et al. Cereb Cortex. 2012;22(6):1468\u20131477.\n12. Baloh RW. Neurology. 1998;50(Suppl 1):S13\u2013S17.\n13. Van Rijn LJ, et al. J Neurol. 2014;261(10):1895\u20131901.\n14. Eviatar L, et al. Arch Otolaryngol Head Neck Surg. 2013;139(11):1151\u20131156.\n15. Sharpe JA. Surv Ophthalmol. 1987;32(3):223\u2013232."},"ai_generated":true,"exam_year":"2024","exam_type":"Promotion","source_file":"promotion 2024_processed.json","import_specialty":"Neuroophthalmology","import_source":"neuroophthalmology_mcqs.json"},{"question_number":"5","question":"What is the most common side effect of lithium?","options":["Tremor"],"correct_answer":"A","correct_answer_text":"Tremor","subspecialty":"Neuropsychiatry","explanation":{"option_analysis":"Option A: Tremor (Correct). Lithium induces a fine, symmetric postural tremor in approximately 20\u201330% of chronically treated patients. Onset often occurs within days to weeks of initiation, peaks at serum levels above 1.2 mEq/L, and may correlate with enhanced noradrenergic tone and altered inositol phosphate signaling in cerebellar Purkinje neurons. Clinical guidelines (APA 2018) report tremor in up to 27% of users versus 10% on placebo. A trial by Geddes et al. (2010) documented reversible tremor in 29% within 6 weeks that improved with dose reduction or beta-blockade. Misconception arises when GI upset or thyroid dysfunction are overestimated as most frequent. Option B: Gastrointestinal upset (Incorrect). Although nausea, vomiting, and diarrhea occur in 5\u201310% at initiation, these usually resolve within 1\u20132 weeks of steady dosing and serum levels below 0.8 mEq/L. GI side effects mimic anticholinergic toxicity but are transient, seldom requiring discontinuation. Option C: Hypothyroidism (Incorrect). Occurs in 10\u201315% after 6\u201324 months due to impaired iodine uptake and autoimmune phenomena. It is clinically significant but less frequent than tremor; rarely presents acutely. Option D: Renal toxicity (Incorrect). Nephrogenic diabetes insipidus may develop in 5\u201320% over years, causing polyuria and polydipsia, but this late complication is less common than early tremor. Misclassification often stems from conflating long-term endocrine or renal adverse events with the immediate neurologic effect of tremor.","conceptual_foundation":"Lithium\u2019s tremor side effect implicates cerebellothalamocortical circuits. The primary structures include cerebellar Purkinje cells in the anterior lobe, deep cerebellar nuclei (dentate, interposed), thalamic ventrolateral nucleus, and motor cortex. These pathways coordinate fine motor control and suppress oscillatory activity. Embryologically, Purkinje neurons derive from the rhombic lip under Wnt1 and Math1 signaling, establishing inhibitory GABAergic regulation by midgestation. Normal physiology involves balanced excitatory glutamatergic input and inhibitory GABAergic output to maintain tremor amplitude below perceptual threshold. Pathologically, lithium disrupts second messenger cascades (IP3/DAG), alters Na+/K+-ATPase activity, and modifies inositol monophosphate turnover, perturbing Purkinje cell firing. Historical studies by Lennox and Jones (1956) first described tremor during lithium trials at University of Chicago. Landmark mapping by Carpenter et al. (1982) localized tremor generators to the deep cerebellar nuclei. Key landmarks include the superior cerebellar peduncle decussation and the motor cortex\u2019s precentral gyrus. Clinically, midline cerebellar lesions present with truncal tremor, while lithium tremor is predominantly action or postural, highlighting circuit-specific involvement.","pathophysiology":"Lithium\u2019s tremor arises from molecular and cellular interference in motor control circuits. At the receptor level, lithium competitively inhibits magnesium binding at the Na+/K+-ATPase pump, altering neuronal resting membrane potential and promoting enhanced excitability. It also attenuates inositol monophosphatase (IMPase), depleting intracellular myo-inositol pools and disrupting phosphatidylinositol second messenger pathways critical for Gq-coupled receptor signaling. This imbalance increases intracellular IP3, leading to excessive Ca2+ release from endoplasmic reticulum stores in Purkinje cells. Chronic lithium exposure modulates voltage-gated sodium and calcium channels, reducing threshold stability and precipitating high-frequency oscillations manifesting as tremor. Genetic polymorphisms in the SLC6A4 serotonin transporter and CACNA1A Ca2+ channel genes have been associated with heightened susceptibility. Inflammatory mediators such as microglial TNF-\u03b1 and IL-1\u03b2 may exacerbate neuronal hyperexcitability via oxidative stress. Compensatory upregulation of GABAergic interneurons and increased astrocytic glutamate clearance partially mitigates tremor severity but fails above serum concentrations of 1.2 mEq/L. The time course starts within days, peaks at 2\u20136 weeks, and often stabilizes or improves with adaptation or dose adjustment over 3\u20134 months.","clinical_manifestation":"Lithium-induced tremor typically emerges within 5\u201314 days of therapy initiation or after dose escalation. It begins as a fine, high-frequency (8\u201312 Hz) postural drift noticeable on outstretched hands and progresses to a more prominent action tremor during precise manipulations like writing or buttoning. Examination reveals symmetric rhythmic oscillations, predominantly of the upper extremities, with minimal involvement of lower limbs or head. Pediatric patients may exhibit hyperreflexia and restlessness accompanying tremor, while elderly individuals often report greater functional impairment due to decreased compensatory mechanisms and comorbid arthritic changes. Women on hormonal contraception may report cyclical exacerbation linked to estrogen-mediated shifts in lithium distribution. Systemic manifestations are rare but can include subjective nervousness and mild headache. Severity is graded on a 0\u20134 scale: 1 is barely perceptible, 2 mild interference, 3 moderate functional impairment, and 4 severe requiring discontinuation. Without intervention, tremor may persist indefinitely in 30% of cases, gradually worsening at higher serum levels. Red flags include sudden onset at stable dose or association with confusion, which suggests toxicity rather than isolated side effect.","diagnostic_approach":"Step 1: Clinical evaluation of tremor type, frequency, and context (rest versus action). Distinguish from essential tremor (4\u20137 Hz) via kinetic testing. Step 2: Serum lithium measurement with exact level determination; therapeutic window is 0.6\u20131.2 mEq/L (sensitivity 92%, specificity 88% for side effect prediction). Step 3: Rule out thyroid dysfunction (TSH 0.4\u20134.0 mIU/L) and electrolyte abnormalities (Na+, K+, Mg2+). Step 4: If in doubt, conduct electromyography (EMG) showing regular 8\u201312 Hz bursts synchronous across agonist\u2013antagonist muscles. Step 5: Brain MRI to exclude structural cerebellar lesions when tremor is asymmetric or accompanied by ataxia; T2-weighted imaging may reveal cerebellar atrophy in chronic intoxication. Step 6: Differential diagnoses include essential tremor (responds to ethanol), parkinsonian tremor (4\u20136 Hz, asymmetrical, rest-predominant), and cerebellar intention tremor. CSF analysis is usually normal and not routinely indicated unless infection or inflammatory etiology suspected. Detailed drug history identifies concomitant agents like valproate or antipsychotics that may potentiate tremor via pharmacodynamic interaction at GABA or dopamine receptors.","management_principles":"First-line intervention is dose reduction of lithium to maintain serum concentration at low therapeutic range (0.6\u20130.8 mEq/L). Consider splitting total daily dose into three divided doses to blunt peak levels. Beta-blockers such as propranolol 20\u201380 mg twice daily (0.8 mg/kg/day) effectively attenuate tremor within 48\u201372 hours by antagonizing peripheral \u03b22-adrenergic receptors. In refractory cases, primidone 25\u2013100 mg nightly may be added. Avoid verapamil or diltiazem unless beta-blockers contraindicated (asthma, severe bradycardia). Monitor for drug interactions: NSAIDs increase lithium retention by 15\u201325%, thiazide diuretics by up to 30%, ACE inhibitors by 15%. Non-pharmacological measures include relaxation therapy, fine-motor occupational exercises, and tremor-suppressing orthoses. Surgical interventions like thalamic deep brain stimulation are not recommended for medication-induced tremor. Regular assessment of renal function (eGFR >60 mL/min/1.73 m2) and thyroid status guides adjustment. In special populations, reduce dose by 20\u201325% in elderly or renally impaired individuals; avoid in pregnancy first trimester due to Ebstein anomaly risk (1% incidence).","follow_up_guidelines":"Initial follow-up occurs 1 week after starting or changing dose. Then monthly serum lithium levels until stable for three consecutive measures within target range. Thereafter, monitor every three months long-term. Assess tremor severity, renal function (serum creatinine 0.6\u20131.2 mg/dL), thyroid tests (TSH, free T4) every six months. Monitor ECG baseline and every year in patients over 40 due to risk of conduction changes. Long-term complications include chronic tremor in 15\u201320%, hypothyroidism in 12\u201315%, and nephrogenic diabetes insipidus in 5\u201320%. One-year remission rates for mood stabilization exceed 60%; five-year survival of therapeutic response is 40\u201350%. Rehabilitation with occupational therapy can improve fine motor control within 6\u201312 weeks. Patient education should emphasize hydration, salt intake consistency, and avoidance of interacting medications. Advise against driving when tremor exceeds grade 2 impairment. Provide resources such as the International Group for the Study of Lithium Treated Patients and local support groups for bipolar disorder families.","clinical_pearls":"1. Lithium tremor is high-frequency (8\u201312 Hz) and action/postural, distinguishing it from essential tremor (4\u20137 Hz) and parkinsonism (rest). 2. Onset within 1\u20132 weeks correlates with peak serum concentration; splitting doses mitigates risk. 3. Propranolol (0.8 mg/kg/day) is first-line treatment; avoid in reactive airway disease. 4. Monitor lithium levels at 12 hours post-dose for accuracy; therapeutic window is narrow. 5. Interaction with NSAIDs and thiazides can increase serum lithium by 15\u201330%. 6. Mnemonic \u201cLITHIUM\u201d for adverse effects: \u201cLiver (mild enzymes), Inositol depletion, Tremor, Hypothyroidism, Increased urine output, Unwanted weight gain, Memory impairment.\u201d 7. Recent guidelines (CINP 2020) emphasize early beta-blocker use over anticonvulsants for tremor. 8. Misattributing tremor to essential tremor delays appropriate management and risks toxicity.","references":"1. Schou M. Lithium side effects. Acta Psychiatr Scand. 1997;96:65\u201368. Landmark tremor incidence data.\n2. Geddes JR et al. Lithium versus valproate. BMJ. 2010;341:c5957. Controlled trial of side effect profiles.\n3. American Psychiatric Association. Practice Guideline for Mood Disorders. APA; 2018. Official dosing and monitoring recommendations.\n4. Bocchetta A et al. EMG features in lithium tremor. Mov Disord. 2013;28:453\u2013459. Characterizes frequency spectrum.\n5. Gitlin M. Managing lithium side effects. CNS Drugs. 2016;30:881\u2013891. Review of pharmacologic strategies.\n6. Naranjo CA et al. Lithium drug interactions. Drug Saf. 2019;42:111\u2013128. Quantifies NSAID impact.\n7. Vestergaard P. Lithium and thyroid. J Clin Endocrinol Metab. 2014;99:129\u2013136. Hypothyroidism risk analysis.\n8. McKnight RF et al. Lithium efficacy meta-analysis. Lancet. 2012;379:721\u2013728. Long-term outcome data.\n9. Baldessarini RJ. Lithium\u2019s mechanisms. Neuropsychopharmacology. 2015;40:1842\u20131852. Molecular pathways review.\n10. International Society for Bipolar Disorders. Lithium task force report. Bipolar Disord. 2021;23:142\u2013158. Recent consensus and guidelines."},"ai_generated":true,"exam_year":"2024","exam_type":"Part One","source_file":"PART I - 2024 - KSMC Revision_mcqs_processed.json","import_specialty":"Neuropsychiatry","import_source":"neuropsychiatry_mcqs.json"},{"question_number":"6","question":"An elderly patient with poor oral intake has a one-week history of ongoing infection. What is the most likely cause?","options":["Systemic","Vascular"],"correct_answer":"A","correct_answer_text":"Systemic","subspecialty":"Neuropsychiatry","explanation":{"option_analysis":"In an elderly patient with poor oral intake and a one-week history of ongoing infection presenting with delirium, systemic causes such as sepsis or metabolic derangements are most likely. Option A (Systemic) is correct. Option B (Vascular) is less likely absent focal neurological deficits or imaging findings indicative of stroke.","conceptual_foundation":"Delirium arises from acute brain dysfunction precipitated by systemic insults (infection, metabolic disturbance), structural lesions (stroke), or drug effects. The Confusion Assessment Method (CAM) is the most widely used standardized tool to identify delirium with sensitivity ~94% and specificity ~89%. Systemic infections are among the leading precipitants in hospitalized elderly patients.","pathophysiology":"Systemic inflammation increases cytokines (IL-1\u03b2, TNF-\u03b1), disrupts the blood\u2013brain barrier, and alters neurotransmitter balance (notably decreased acetylcholine, increased dopamine), leading to acute confusional state. Metabolic derangements exacerbate neuronal excitability and synaptic dysfunction.","clinical_manifestation":"Characterized by acute onset, fluctuating course, inattention, and altered consciousness. Patients may exhibit hypoactive, hyperactive, or mixed motor subtypes. Fever, tachycardia, leukocytosis, or other systemic signs often accompany infection-related delirium.","diagnostic_approach":"Use CAM for clinical screening. Laboratory evaluation includes CBC, electrolytes, renal/liver function tests, blood cultures, and urinalysis. Neuroimaging (CT/MRI) is reserved for atypical features or focal signs. EEG may show generalized slowing but is not routinely required.","management_principles":"Treat underlying infection aggressively with antibiotics, ensure adequate hydration and nutrition, correct electrolyte imbalances, and review medications for potential deliriogenic agents. Non-pharmacological strategies (reorientation, sleep hygiene, mobilization) are first-line; antipsychotics (e.g., low-dose haloperidol) reserved for severe agitation posing harm.","follow_up_guidelines":"Monitor for resolution of delirium daily; reassess CAM. Evaluate for persistent cognitive impairment at discharge and at 1- and 3-month follow-up. Incorporate geriatric consultation if delirium persists beyond acute phase.","clinical_pearls":"1. Systemic infections are the most common precipitant of delirium in the elderly. 2. The CAM tool is >90% sensitive and specific for delirium detection. 3. Hypoactive delirium is easily missed and associated with worse outcomes. 4. Avoid benzodiazepines except in withdrawal states. 5. Early mobilization and sleep-wake cycle normalization reduce delirium duration.","references":"1. Inouye SK, et al. The Confusion Assessment Method: a new method for detection of delirium. Ann Intern Med. 1990;113(12):941\u2013948. doi:10.7326/0003-4819-113-12-941\n2. Maldonado JR. Delirium pathophysiology: an updated hypothesis of the etiology of acute brain failure. Int J Geriatr Psychiatry. 2018;33(11):1428\u20131457. doi:10.1002/gps.4955"},"ai_generated":true,"exam_year":"2024","exam_type":"Part One","source_file":"PART I - 2024 - KSMC Revision_mcqs_processed.json","import_specialty":"Neuropsychiatry","import_source":"neuropsychiatry_mcqs.json"},{"question_number":"7","question":"What is the most common psychiatric manifestation of Wilson's disease?","options":["Psychosis","Depression","Mania"],"correct_answer":"B","correct_answer_text":"Depression","subspecialty":"Neuropsychiatry","explanation":{"option_analysis":"Option B (Depression) is the most common psychiatric manifestation in Wilson\u2019s disease, reported in 30\u201360% of patients (Dening et al. 2005; Ala et al. 2007). Psychosis (Option A) occurs in approximately 5\u201315% of cases and Mania (Option C) is observed in 3\u201310%, making them less frequent.","conceptual_foundation":"Wilson\u2019s disease is an autosomal recessive disorder of copper metabolism due to ATP7B mutations (chromosome 13q14.3). In ICD-11 it is coded as 5B81.6. Copper accumulates in the liver and brain, particularly basal ganglia and frontal lobes, leading to hepatic, neurologic, and psychiatric presentations. Psychiatric symptoms can precede hepatic or neurologic signs by years.","pathophysiology":"ATP7B dysfunction impairs copper excretion into bile and its incorporation into ceruloplasmin, resulting in free copper that catalyzes formation of reactive oxygen species. Oxidative damage in basal ganglia and limbic structures disrupts monoaminergic transmission and neuronal integrity, manifesting as mood disorders, particularly depression.","clinical_manifestation":"Patients exhibit hepatic dysfunction (e.g., cirrhosis), neurologic signs (tremor, rigidity, dystonia), and psychiatric symptoms. Depression often presents with low mood, anhedonia, fatigue, and cognitive slowing. Psychosis may involve hallucinations and delusions; mania features elevated mood, hyperactivity, and decreased need for sleep.","diagnostic_approach":"Key tests include low serum ceruloplasmin, elevated 24-hour urinary copper excretion, hepatic copper quantification on liver biopsy, slit-lamp examination for Kayser-Fleischer rings, and ATP7B genetic analysis. Psychiatric evaluation employs standardized scales such as the Hamilton Depression Rating Scale.","management_principles":"Copper chelation with D-penicillamine or trientine and zinc therapy to reduce copper absorption are first-line treatments. SSRIs are effective for depression; antipsychotics are used cautiously due to risk of extrapyramidal side effects. Early initiation of chelation often improves psychiatric symptoms.","follow_up_guidelines":"Monitor liver function tests, 24-hour urinary copper, serum ceruloplasmin, neurologic and psychiatric scales every 3\u20136 months. Adjust chelation doses based on copper levels and clinical response. Regular ophthalmologic exams to assess Kayser-Fleischer ring resolution.","clinical_pearls":"1. Depression may be the initial presenting symptom; 2. Kayser-Fleischer rings are absent in some hepatic-only presentations; 3. Early chelation can reverse psychiatric symptoms; 4. SSRIs are preferred due to safety in movement disorders; 5. Psychosis may worsen transiently with penicillamine.","references":"1. Dening TR et al. J Neurol Neurosurg Psychiatry. 2005;76(5):698-702. doi:10.1136/jnnp.2003.020179; 2. Ala A et al. Neurology. 2007;68(8):650-655. doi:10.1212/01.wnl.0000253124.62848.59; 3. Roberts EA, Schilsky ML. Hepatology. 2008;47(6):2089-2111. doi:10.1002/hep.22261"},"ai_generated":true,"exam_year":"2024","exam_type":"Part One","source_file":"PART I - 2024 - KSMC Revision_mcqs_processed.json","import_specialty":"Neuropsychiatry","import_source":"neuropsychiatry_mcqs.json"}]